Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quality of life study of palonosetron and dexamethasone in chemonaive patinets with advanced colorectal cancer treated with moderateemetic chemotherapy

ABSTRACT: Interventions: palonosetoron and dexamethasone Primary outcome(s): MAT(MASCC Antiemesis Tool) QOL-ACD(The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs) Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer Recieving Moterate Emetic Chemotherapy

PROVIDER: 2623343 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

16S rRNA gene sequence analysis of feces samples from 60 breast cancer patients treated with paclitaxel and 20 healthy controls

Project description:We randomly selected 60 patients who completed paclitaxel treatment for high-throughput sequencing. Grade 2 or higher (grade 2+) neuropathy has been defined as high-PIPN and Grade 1 as low-PIPN according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE version 4.0) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20). We compared gut microbiome signatures in high-PIPN, low-PIPN, and healthy controls.

2023-10-12 | E-MTAB-13423 | biostudies-arrayexpress

Rat liver: Dexamethasone treatment vs. Control

Project description:Sixteen male Sprague-Dawley rats were randomly allocated into 2 groups (8 rats per group) as follows: the control group (CON) and the dexamethasone-treated group (DEXA). Dexamethasone-treated rats received a daily intraperitoneal injection of 1.5 mg/kg of dexamethasone for 5 days. All rats were fasted during the night following the fifth day. On the sixth day, the animals were killed by decapitation. In order to focus our investigation on metabolism-related genes, we developed a metabolism dedicated microarray tool: the Mitoligo. Using this microarray tool, we were able to determine that energy metabolism was deeply modified by dexamethasone treatment. Dexamethasone treatment to rats induces a complete switch of the metabolism toward a maximal rate of ATP synthesis. In this study, we show that substrate supplying for oxidative phosphorylation is greatly enhanced. We also confirm that oxidative phosphorylation capacity is increased by dexamethasone treatment. Keywords: hormonal treatment

2008-01-13 | GSE9035 | GEO

Efficacy and safety of palonosetron and dexamethasone in patients who haven’t responded to conventional antiemetic agents; granisetron and dexamethasone

Project description:Interventions: Day 1 Palonosetoron 0.75mg/body and dexamethasone 12mg/body should be administered 30 minutes prior to chemotherapy Day 2-3 Dexamethasone 4mg/body should be administered orally. Primary outcome(s): Complete Response rate Study Design: Single arm Non-randomized

| 2624980 | ecrin-mdr-crc

Trancriptional signatures of dexamethasone-treated sarcoidosis monocytes.

Project description:The goal of this study was to determine the effect of dexamethasone treatment on trancriptional sigantures and pathways of sarcoidosis monocytes.

2020-05-20 | GSE150049 | GEO

Trancriptional signatures of dexamethasone-treated sarcoidosis monocytes.

Project description:Trancriptional signatures of dexamethasone-treated sarcoidosis monocytes.

| PRJNA630995 | ENA

Genome-wide analysis of dexamethasone treated substrates in HeLa cell

Project description:Analysis of dexamethasone treated substrates during 3 hr in HeLa cell.

2015-02-22 | GSE49591 | GEO

Trancriptional signatures of dexamethasone-treated sarcoidosis alveolar macrophages (AMs)

Project description:The goal of this study was to determine the effect of dexamethasone treatment on trancriptional signatures and pathways of sarcoidosis AMs.

2020-05-20 | GSE150842 | GEO

The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation

Project description:Dexamethasone is a life-saving treatment for severe COVID-19, yet its mechanism of action is unknown, and many patients deteriorate or die despite timely treatment initiation. Here, we identify dexamethasone treatment-induced cellular and molecular changes associated with improved survival in COVID-19 patients. We observed a reversal of transcriptional hallmark signatures in monocytes associated with severe COVID-19 and the induction of a monocyte substate characterized by the expression of glucocorticoid-response genes. These molecular responses to dexamethasone were detected in circulating and pulmonary monocytes, and they were directly linked to survival. Monocyte single-cell RNA sequencing (scRNA-seq)-derived signatures were enriched in whole blood transcriptomes of patients with fatal outcome in two independent cohorts, highlighting the potential for identifying non-responders refractory to dexamethasone. Our findings link the effects of dexamethasone to specific immunomodulation and reversal of monocyte dysregulation, and they highlight the potential of single-cell omics for monitoring in vivo target engagement of immunomodulatory drugs and for patient stratification for precision medicine approaches.

2024-07-04 | GSE270901 | GEO

Post-Op Quality of Life After Colorectal Surgery

Project description:The purpose of this study is to produce a user-friendly tool- in the form of a questionnaire - to accurately assess early quality of life in patients after abdominal colorectal surgery from the first day after surgery to 6 months after. The study will also compare this questionnaire to the other currently available assessment tools. Patients are invited to participate if they are undergoing abdominal colorectal surgery at University Hospitals of Cleveland.

| 2039614 | ecrin-mdr-crc

Nascent transcriptional profiling of CEM-C7 ALL cells treated with dexamethasone

Project description:The glucocorticoid receptor (GR) is a transcription factor that localizes to the nucleus and reuglates gene expression upon binding of a glucocorticoid ligand such as dexamethasone. We perform nascent transcriptional profiling of C7 ALL cells following treatment with dexamethasone to evaluate the immediate transcriptional effects of GR. We find 51 dynamic genes (46 activated, 5 repressed) after 1 hour treatment and 141 dynamic genes (70 activated and 71 repressed) after 4 hour treatment. We input RNA polymerase density in pause and gene body regions into a mathematical model designed to quantify rate changes of individual transcriptional steps. We find that dexamethasone treatment primarily activates genes by inducing pause release rate.

2022-12-04 | GSE219041 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data